Evidence map›Paper›PMID 30056798›Full record

ArticleEpigenetics2018

Epigenetics of gastrointestinal diseases: notes from a workshop.

David L Marks, Rachel L Olson, Raul Urrutia, Daniel D Billadeau, Nilotpal Roy, George A Calin, Muller Fabbri, Marina Koutsioumpa, Dimitrios Iliopoulos, Tamas Ordog and 13 more

Open access · hybridAbstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Epigenetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 11 institutions in 4 countries.

David L Marksa Schulze Center for Novel Therapeutics, Division of Oncology Research , Mayo Clinic , Rochester , MN , USA.
Rachel L Olsona Schulze Center for Novel Therapeutics, Division of Oncology Research , Mayo Clinic , Rochester , MN , USA.
Raul Urrutiab Division of Research, Department of Surgery , Medical College of Wisconsin , Milwaukee , WI , USA.
Daniel D Billadeaua Schulze Center for Novel Therapeutics, Division of Oncology Research , Mayo Clinic , Rochester , MN , USA.
Nilotpal Royc Diabetes Center , University of California at San Francisco , San Francisco , CA , USA.
George A Calind Department of Experimental Therapeutics, Division of Cancer Medicine , MD Anderson Cancer Center , Houston , TX , USA.
Muller Fabbrie Children's Center for Cancer and Blood Diseases, Keck School of Medicine of USC , University of Southern California , Los Angeles , CA , USA.
Marina Koutsioumpaf Laboratory and the Center for Systems Biomedicine , University of California at Los Angeles , Los Angeles , CA , USA.
Dimitrios Iliopoulosf Laboratory and the Center for Systems Biomedicine , University of California at Los Angeles , Los Angeles , CA , USA.
Tamas Ordogg Division of Gastroenterology, Department of Medicine , Mayo Clinic , Rochester , MN , USA.
Robert Huebertg Division of Gastroenterology, Department of Medicine , Mayo Clinic , Rochester , MN , USA.ORCID 0000-0002-9812-7573
Olga Sarmentog Division of Gastroenterology, Department of Medicine , Mayo Clinic , Rochester , MN , USA.
Adebowale O Bamideleg Division of Gastroenterology, Department of Medicine , Mayo Clinic , Rochester , MN , USA.ORCID 0000-0002-9547-2195
William Faubiong Division of Gastroenterology, Department of Medicine , Mayo Clinic , Rochester , MN , USA.
Gwen L Lomberkb Division of Research, Department of Surgery , Medical College of Wisconsin , Milwaukee , WI , USA.ORCID 0000-0001-5463-789X
Jens Sivekeh Division of Solid Tumor Translational Oncology, West German Cancer Center , University Hospital Essen , Essen , Germany.ORCID 0000-0002-8772-4778
Nita Ahujai Department of Surgery , Yale School of Medicine , New Haven , CT , USA.
Juan Iovannaj Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258 , Institut Paoli-Calmettes , Aix Marseille , France.ORCID 0000-0003-1822-2237
Ryan A Hladyk Department of Molecular Pharmacology and Experimental Therapeutics , Mayo Clinic , Rochester , MN , USA.
Keith Robertsonk Department of Molecular Pharmacology and Experimental Therapeutics , Mayo Clinic , Rochester , MN , USA.
John Kisielg Division of Gastroenterology, Department of Medicine , Mayo Clinic , Rochester , MN , USA.
Christopher L Pinl Division of Genetics & Development, Children's Health Research Institute, Departments of Pediatrics, Physiology and Pharmacology, and Oncology , The University of Western Ontario , London , ON , Canada.
Martin E Fernandez-Zapicoa Schulze Center for Novel Therapeutics, Division of Oncology Research , Mayo Clinic , Rochester , MN , USA.
Mayo Clinic · USMayo Clinic in Arizona · USMedical College of Wisconsin · USUniversity of California, Los Angeles · USCentre National de la Recherche Scientifique · FREssen University Hospital · DEThe University of Texas MD Anderson Cancer Center · USUniversity of California, San Francisco · USUniversity of Southern California · USWestern University · CAYale University · US

Funding

Physiological Characterization and Data Integration CoreP01DK068055 · NIDDK · MAYO CLINIC ROCHESTER · PI BHARUCHA, ADIL E. · 2004 to 2019
$23.8M
PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI GREGORY J. GORES · 2009 to 2026
$22.2M
Pilot and FeasibilityP30DK090728 · NIDDK · MAYO CLINIC ROCHESTER · PI ROMERO, MICHAEL F. · 2010 to 2019
$11.8M
ZINC FINGER GENES AND PANCREATIC CELL GROWTHR01DK052913 · NIDDK · MEDICAL COLLEGE OF WISCONSIN · PI LOMBERK, GWEN, URRUTIA, RAUL A. · 1998 to 2023
$7.0M
Interstitial Cells of Cajal in Diabetic GastropathyR01DK058185 · NIDDK · UNIVERSITY OF NEVADA RENO · PI ORDOG, TAMAS · 2002 to 2020
$5.2M
Novel Experimental Therapeutics for Pancreatic CancerR01CA178627 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI LOMBERK, GWEN · 2014 to 2018
$1.6M
miRNA Regulation of Aquaporin 1 Modulates Vascular Remodelling during CirrhosisK08DK100575 · NIDDK · MAYO CLINIC ROCHESTER · PI HUEBERT, ROBERT CHRISTIAN · 2013 to 2017
$757k
Epigenetic Regulation in Primary Sclerosing CholangitisR03DK113339 · NIDDK · MAYO CLINIC ROCHESTER · PI HUEBERT, ROBERT CHRISTIAN · 2018 to 2019
$159k
NCI NIH HHS R01 CA178627NIDDK NIH HHS K08 DK100575NIDDK NIH HHS P01 DK068055NIDDK NIH HHS P30 DK084567NIDDK NIH HHS P30 DK090728NIDDK NIH HHS R01 DK052913NIDDK NIH HHS R01 DK058185NIDDK NIH HHS R03 DK113339
6 · The paper itself

Abstract

International experts gathered at the Mayo Clinic (Rochester MN, USA) on February 27th-28th, 2017 for a meeting entitled 'Basic and Translational Facets of the Epigenetics of GI Diseases'. This workshop summarized recent advances on the role of epigenetics in the pathobiology of gastrointestinal (GI) diseases. Highlights of the meeting included recent advances on the involvement of different epigenetic mechanisms in malignant and nonmalignant GI disorders and the epigenetic heterogeneity exhibited in these diseases. The translational value of epigenetic drugs, as well as the current and future use of epigenetic changes (i.e., DNA methylation patterns) as biomarkers for early detection tools or disease stratification were also important topics of discussion.

Indexed as

Epigenesis, GeneticDNA MethylationGastrointestinal DiseasesGenetic HeterogeneityGenetic MarkersHumansTranslational Research, BiomedicalGenetic MarkersbiomarkerschromatinDNA methylationepigeneticsGastrointestinal diseasesmiRNAtherapeutics

Identifiers

PMID30056798
PMCPMC6140811
OpenAlexW2885739537

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.